Don’t miss out on the next big thing in the life sciences.

Rick Batycky, President & CEO, Nocion Therapeutics

In this Q&A, Batycky explains what drew him to the Nocion platform and its novel class of charged sodium channel blockers, how the company’s locally delivered approach to silencing overactive sensory nerves differs fundamentally from the oral therapies dominating the field, and why the ASPIRE Phase 2b trial — with a data readout expected later this year — represents a defining moment for the company. He also discusses the pipeline opportunity beyond cough, the lean and gritty culture he has built at Nocion, and why he believes the industry’s reluctance to talk openly about failure is one of the costliest habits in drug development.